Matin S - Search Results

1

Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals.

Shapiro DD, Karam JA, Zemp L, Master VA, Sexton WJ, Ghasemzadeh A, Schmeusser BN, Davaro F, Peak T, Patil D, Matin S, Spiess PE, Abel EJ. Shapiro DD, et al. Among authors: matin s. Eur Urol Open Sci. 2023 Feb 18;50:43-46. doi: 10.1016/j.euros.2023.01.016. eCollection 2023 Apr. Eur Urol Open Sci. 2023. PMID: 36861106 Free PMC article.

2

Port-site metastasis: the influence of biology.

Highshaw RA, Vakar-Lopez F, Jonasch E, Yasko AW, Matin SF. Highshaw RA, et al. Eur Urol. 2005 Mar;47(3):357-60. doi: 10.1016/j.eururo.2004.11.008. Epub 2005 Jan 15. Eur Urol. 2005. PMID: 15716201

3

Laparoscopic cytoreductive nephrectomy: the M. D. Anderson Cancer Center experience.

Matin SF, Madsen LT, Wood CG. Matin SF, et al. Urology. 2006 Sep;68(3):528-32. doi: 10.1016/j.urology.2006.03.076. Epub 2006 Sep 18. Urology. 2006. PMID: 16979706

4

Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study.

Matin SF, Ahrar K, Cadeddu JA, Gervais DA, McGovern FJ, Zagoria RJ, Uzzo RG, Haaga J, Resnick MI, Kaouk J, Gill IS. Matin SF, et al. J Urol. 2006 Nov;176(5):1973-7. doi: 10.1016/j.juro.2006.07.016. J Urol. 2006. PMID: 17070224

5

Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience.

Kader AK, Tamboli P, Luongo T, Matin SF, Bell K, Jonasch E, Swanson DA, Wood CG. Kader AK, et al. J Urol. 2007 Mar;177(3):855-60; discussion 860-1. doi: 10.1016/j.juro.2006.10.058. J Urol. 2007. PMID: 17296358

6

Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.

Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG. Margulis V, et al. J Urol. 2008 Jul;180(1):94-8. doi: 10.1016/j.juro.2008.03.047. Epub 2008 May 15. J Urol. 2008. PMID: 18485389

7

Cytoreductive nephrectomy in metastatic renal cell carcinoma.

Margulis V, Matin SF, Wood CG. Margulis V, et al. Curr Opin Urol. 2008 Sep;18(5):474-80. doi: 10.1097/MOU.0b013e32830a4f21. Curr Opin Urol. 2008. PMID: 18670270 Review.

8

Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma.

Margulis V, Matin SF, Tannir N, Tamboli P, Shen Y, Lozano M, Swanson DA, Jonasch E, Wood CG. Margulis V, et al. Urology. 2009 Feb;73(2):337-41. doi: 10.1016/j.urology.2008.08.476. Epub 2008 Oct 31. Urology. 2009. PMID: 18950837 Free PMC article. Clinical Trial.

9

Predictors of unilateral renal function after open and laparoscopic partial nephrectomy.

Chan AA, Wood CG, Caicedo J, Munsell MF, Matin SF. Chan AA, et al. Urology. 2010 Feb;75(2):295-302. doi: 10.1016/j.urology.2009.09.027. Epub 2009 Dec 5. Urology. 2010. PMID: 19963245

10

Identifying the risk of disease progression after surgery for localized renal cell carcinoma.

Abel EJ, Culp SH, Meissner M, Matin SF, Tamboli P, Wood CG. Abel EJ, et al. BJU Int. 2010 Nov;106(9):1277-83. doi: 10.1111/j.1464-410X.2010.09337.x. BJU Int. 2010. PMID: 20394619

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

454 results

Search Page